GSK’s asthma push continues as drug succeeds in Phase 3 trials

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In